Ray Miller
Partner
Nicole Endejann
Associate
Tom Petzinger
Executive Vice President of Business Development and Public Affairs
Knopp Neurosciences, Inc.
Raymond A. Miller and N. Nicole Endejann, Pittsburgh attorneys in Pepper Hamilton’s Intellectual Property Practice and Life Sciences Practice, and Tom Petzinger, Executive Vice President of Business Development and Public Affairs of Knopp Neurosciences Inc., identify the intellectual property and regulatory exclusivity strategies necessary for emerging life science companies to secure investments, strategic partnerships or licenses with third parties. In addition to reviewing critical IP strategies, this podcast discusses the recent Knopp – Biogen Idec transaction, in which Pepper served as IP counsel. Knopp developed the drug, dexpramipexole, for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and potentially other indications. In August, Biogen Idec and Knopp Neurosciences entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize the drug.
Email podcasts@pepperlaw.com to subscribe to Pepper Hamilton’s IP Alerts and Updates.
(Running Time: 26:28)
MP3 File
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83456298769e20134880dcf2b970c
Listed below are links to weblogs that reference Integration of IP and Regulatory Exclusivity Strategies for Emerging Life Science Companies:
(audio files only)
(audio + text)
